About Recludix Pharma
Recludix Pharma is a Healthcare company based in San Diego (United States) founded in 2020. Provider of the online platform for drug discovery and development. Recludix Pharma has raised $60 million across 1 funding round from investors including Westlake BioPartners, NEA and Access Industries. The company has 33 employees. Its chief executive, as recorded, is Nancy Whiting. Recludix Pharma offers products and services including STAT6 Program, STAT3 Program, and BTK Program. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is RECLUDIX PHARMA, INC. Its competitors include Insitro, Helix and Certara; 2 of its 3 listed competitors have raised funding.
Company details
Recludix Pharma was founded in 2020 and is based in San Diego, United States. An online platform is offered by the company for drug discovery and development within the biotechnology sector. Researchers are assisted through the platform in identifying and predicting potent sites on STAT 3 and STAT 6 proteins. These targets are linked to cancer and inflammatory conditions, including rheumatoid arthritis, asthma, and atopic dermatitis.
- Headquarters San Diego, United States
- Employees 33
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website recludixpharma.com
- Social LinkedIn
- Legal Name Recludix Pharma, Inc.
- Total Equity Funding$60M (USD)
in 1 rounds
- Latest Funding Round$60M (USD), Series A
Nov 2021
- InvestorsWestlake BioPartners
& 2 more
- Employee Count33
Products & Services of Recludix Pharma
Recludix Pharma offers a comprehensive portfolio of products and services, including STAT6 Program, STAT3 Program, and BTK Program.
Targets SH2 domains for treating inflammatory diseases.
Focuses on protein interactions in inflammatory conditions.
Develops therapies for inflammation via key protein pathways.
Funding Insights of Recludix Pharma
Recludix Pharma has successfully raised a total of $60M through 1 strategic funding round. The most recent funding activity was a Series A round of $60 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $60M
- Total Rounds 1
- Last Round Series A — $60M
- First Round $60M
(Nov 2021)
- Investors Count 3
All 1 funding rounds of Recludix Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $60M | Series A | – | Westlake Village Biopartners, New Enterprise Associates | – |
3 investors in total: 3 institutional.
Investors in Recludix Pharma
Recludix Pharma has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Westlake BioPartners, NEA and Access Industries.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Westlake BioPartners is engaged in biotech venture capital investment. | westlakebio.com | Westlake Village, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Investment and holding company controlled by Len Blavatnik | accessindustries.com | New York, United States |
Investor details for Recludix Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Recludix Pharma
36 people are tracked at Recludix Pharma (15 in leadership, 12 in board & advisors, 9 in team); the tracked headcount is 33.
| Name | Role | Group |
|---|---|---|
Nancy Whiting | CEO | Leadership |
Matthew Caldemeyer | Chief Business Officer | Leadership |
Ajay Nirula | Executive Vice President | Leadership |
Sean Kim | Vice President - DMPK | Leadership |
Alexandra Gardino | Senior Director | Leadership |
Rishi Vaswani | Senior Director | Leadership |
Allen Sickmier | Senior Director; Head of Protein Sciences and Structural Biology | Leadership |
Neil Bifulco | Sr. Director Of Medicinal Chemistry | Leadership |
Jeremy Hunt | Director, Drug Discovery Technology | Leadership |
Lynne Liesberg | Senior Director, Controller | Leadership |
Ryan Diviney | Senior Director Human Resources | Leadership |
Gordon Wilkie | Head Of Chemistry, Manufacturing, And Controls | Leadership |
Claudia Harper | Senior Vice President, Nonclinical Development | Leadership |
Xia Tian | Director Medicinal Chemistry | Leadership |
Samuel Reznik | Director of Medicinal Chemistry | Leadership |
Stefan Knapp | Advisor | Board & advisors |
Marco Londei | Advisor | Board & advisors |
Jeff Tyner | Advisor | Board & advisors |
Liam Ratcliffe | Director | Board & advisors |
Carlos Garcia-Echeverria | Advisor | Board & advisors |
16 more people are available in the full profile.
Complete people profiles for Recludix Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Recludix Pharma
2 dated milestones of Recludix Pharma across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Recludix Pharma is founded.
- Funding First funding round of $60.0M.
Competitors of Recludix Pharma
Recludix Pharma has 3 listed competitors in our database, 2 of them funded. They include Insitro, Helix and Certara.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| helix.com | 2015 | San Francisco, United States | $435M | Genomic database for clinical research is provided. | ||
| certara.com | 2008 | Princeton, United States | 827 | Provider of a platform for in silico drug discovery and consulting services |
Detailed competitors of Recludix Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Recludix Pharma
The website of Recludix Pharma (recludixpharma.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▲ 43.3% vs previous month
Websites whose visitors overlap most with Recludix Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alfascientific.com | 100% | #8,547,751 | View details | ||
convergencechurchnetwork.com | convergencechurchnetwork.com | 100% | #3,171,034 | – | |
| carihealth.com | 100% | View details | |||
conventusbiomed.com | conventusbiomed.com | 99% | – | ||
| zerigohealth.com | 97% | 5.4K | #3,508,305 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Recludix Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Recludix Pharma (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Recludix Pharma
Complete news archive for Recludix Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Recludix Pharma
Recludix Pharma was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Recludix Pharma is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Nancy Whiting is the CEO of Recludix Pharma, as recorded in our data.
Recludix Pharma is a funded company, having raised a total of $60M across 1 funding round to date. The company's 1st funding round was a Series A of $60M, raised on Nov 2021.
Recludix Pharma has 33 employees.
Recludix Pharma was founded in 2020 and is based in San Diego, United States. An online platform is offered by the company for drug discovery and development within the biotechnology sector. Researchers are assisted through the platform in identifying and predicting potent sites on STAT 3 and STAT 6 proteins. These targets are linked to cancer and inflammatory conditions, including rheumatoid arthritis, asthma, and atopic dermatitis.
Recludix Pharma offers STAT6 Program, STAT3 Program, and BTK Program.
Recludix Pharma has 3 investors. Key investors include Westlake BioPartners, NEA, and Access Industries.
Recludix Pharma operates through Recludix Pharma, Inc..